Cernitol 47 mg is now available for sale in France. During a scientific seminar held by Cernelle September 10th in Toulouse, Cernitol was introduced successfully to French urologists and pharmacists.
The topic at this symposium was “inflammation in the prostate and chronic pelvic pain”, whereby highly recognised urologists held interesting lectures with new data and views of these diseases.
About AB Cernelle: Cernelle is a Swedish pharmaceutical company with research and development of medicine in urology; chronic prostatitis/pelvic pain syndrome (CP/CPPS) and benign prostate hyperplasia (BPH). Cernelle has developed herbal pharmaceuticals from pure pollen extract since 1953. With over 50 million daily doses per year, Cernilton®/Cernitol® is one of the world's most used medicine to treat benign prostate diseases.
The company have 40 employees, located at the facilities outside Ängelholm in Southern Sweden. Cernelle is owned by Backahill AB since 2005.